Status:
COMPLETED
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
Lead Sponsor:
AbbVie
Conditions:
Parkinson's Disease (PD)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
Detailed Description
Participants with advanced Parkinson's Disease who have been prescribed LCIG for at least 12 months will be entered into the study cohort. Clinical data will be collected by retrospective review of th...
Eligibility Criteria
Inclusion
- Participants diagnosed with APD and on LCIG treatment for at least 12 months
- Participant must have been on continuous LCIG treatment for at least 80% of days in the preceding year
- Participants must be treated by the same physician (principal investigator or co-investigator) since the initiation of LCIG treatment
Exclusion
- Participation in a concurrent or a previous interventional clinical trial during which the participant was on LCIG therapy
- Lack of motivation or insufficient language skills to complete the study questionnaires
Key Trial Info
Start Date :
December 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 17 2018
Estimated Enrollment :
412 Patients enrolled
Trial Details
Trial ID
NCT03362879
Start Date
December 14 2017
End Date
December 17 2018
Last Update
January 6 2020
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Gailtal Klinik /ID# 202505
Hermagor-Pressegger See, Carinthia, Austria, 9620
2
Medizinische Universität Graz /ID# 202559
Graz, Styria, Austria, 8010
3
University of Calgary /ID# 206550
Calgary, Alberta, Canada, T2N 4Z6
4
Ottawa Hospital /ID# 169448
Ottawa, Ontario, Canada, K1Y 4E9